SMMT Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Summit Therapeutics's net margin of 21.68%. Summit Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.77%. On the other hand Eli Lilly and has an analysts' consensus of $972.57 which suggests that it could grow by 30.36%. Given that Summit Therapeutics has higher upside potential than Eli Lilly and, analysts believe Summit Therapeutics is more attractive than Eli Lilly and.

Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Summit Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Summit Therapeutics's net income of -$62.9M is lower than Eli Lilly and's net income of $2.8B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 60.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,729.72x versus 13.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Summit Therapeutics's net margin of 32.71%. Summit Therapeutics's return on equity of -- beat Merck &'s return on equity of 39.02%.

Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.77%. On the other hand Merck & has an analysts' consensus of $104.67 which suggests that it could grow by 36.6%. Given that Summit Therapeutics has higher upside potential than Merck &, analysts believe Summit Therapeutics is more attractive than Merck &.

Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.12% to investors and pays a quarterly dividend of $0.81 per share. Summit Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Summit Therapeutics quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Summit Therapeutics's net income of -$62.9M is lower than Merck &'s net income of $5.1B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,729.72x versus 3.04x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Summit Therapeutics's net margin of 21.63%. Summit Therapeutics's return on equity of -- beat Pfizer's return on equity of 8.72%.

Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.77%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 28.98%. Given that Summit Therapeutics has higher upside potential than Pfizer, analysts believe Summit Therapeutics is more attractive than Pfizer.

Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.43% to investors and pays a quarterly dividend of $0.43 per share. Summit Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Summit Therapeutics's net income of -$62.9M is lower than Pfizer's net income of $3B. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,729.72x versus 2.09x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Instil Bio has a net margin of -- compared to Summit Therapeutics's net margin of --. Summit Therapeutics's return on equity of -- beat Instil Bio's return on equity of --.

Summit Therapeutics has a consensus price target of $37.31, signalling upside risk potential of 51.77%. On the other hand Instil Bio has an analysts' consensus of $113.67 which suggests that it could grow by 792.2%. Given that Instil Bio has higher upside potential than Summit Therapeutics, analysts believe Instil Bio is more attractive than Summit Therapeutics.

Summit Therapeutics has a beta of -0.940, which suggesting that the stock is 194.025% less volatile than S&P 500. In comparison Instil Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Summit Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instil Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics pays -- of its earnings as a dividend. Instil Bio pays out -- of its earnings as a dividend.

Summit Therapeutics quarterly revenues are --, which are smaller than Instil Bio quarterly revenues of --. Summit Therapeutics's net income of -$62.9M is lower than Instil Bio's net income of -$11.9M. Notably, Summit Therapeutics's price-to-earnings ratio is -- while Instil Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics is 18,729.72x versus -- for Instil Bio. Usually stocks with elevated PS ratios are considered overvalued.